Cerebral Palsy (CP) is a common (about 1 in 500 children) health condition caused by abnormal brain development that affects the ability to control movement. Early risk assessment happens through the General Movements Assessment (GMA), a test administered by trained clinicians at 3-4 months of age that has high predictive value for CP. With recent improvements in video-based motion tracking, automated risk assessment for CP based on the GMA is being explored. However, studies generally have used small datasets or were limited in terms of methodological rigor. Here we acquired a large dataset (1060 infants) of videos from a clinical population with elevated CP risk. In a preregistered pipeline using a lock-box set that was not used before algorithm submission we find that our machine learning predictions are highly predictive of the clinician-assessed GMA (AUC=0.79). Given its low cost, our video-based approach may be useful for clinical screening applications, particularly in low-resource settings.

The authors have declared no competing interest.

This work was funded by NIH-NICHD and the clinical early detection trial data collection was supported in part by the Cerebral Palsy Foundation

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of The University of Pennsylvania (Penn) gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes